Metabolon Announces Speaker Presentations at European Association for the Study of Diabetes Meeting
Analyses of biomarkers provides insight into insulin resistance related to type 2 diabetes and fatty liver disease and the effects of insulin sensitizer therapy in T2D prevention study
RESEARCH TRIANGLE PARK, N.C. (September 13, 2011) — Metabolon, Inc., the leader in metabolomics, biomarker discovery and biochemical analysis, announced today that they will give three presentations representing the company’s research into biomarkers at the European Association for the Study of Diabetes (EASD) Meeting in Lisbon, Portugal September 12-18. Also presenting the EASD’s 43rd Claude Bernard keynote lecture is Metabolon collaborator, Ele Ferrannini, MD Professor of Medicine, University of Pisa, Italy, on Friday, September 16th. The lecture is from 1:00 p.m.- 2:00 p.m. and is entitled “Diabetes: Brief History of a Conspiracy”. Please Note: UNDER EMBARGO until 1:01 p.m. on 9/16
The first of two oral presentations (Oral Presentation number 55) for Metabolon will take place on Tuesday, September 13th at 2:45 p.m.:
“Pioglitazone Improves Insulin Sensitivity by Modulating Novel Biomarkers: Results from the ACT NOW Study” will be presented by Ralph DeFronzo, M.D., Professor, Chief Diabetes Division, University of Texas Health Science Center at San Antonio. The study determined that pioglitazone modulates novel metabolites related to lipid metabolism and oxidative stress, which may in part explain the beneficial effects of pioglitazone on insulin sensitivity.
The second oral presentation (Oral Presentation number 228) takes place Friday, September 16th from 10:15 a.m.-11:15 a.m.:
“Metabolic Markers of Insulin Sensitivity Predict Progression to IGT and T2D”, will be presented by Walt Gall, Ph.D., Metabolon, Inc.; the study demonstrated that the measurement of a panel of insulin resistance markers in a fasting plasma sample can identify high-risk insulin resistant subjects with high accuracy. This measurement can also predict the progression to impaired glucose tolerance and type 2 diabetes. Please Note: UNDER EMBARGO until 10:16 a.m. on 9/16
Metabolon will also have a poster presentation on Wednesday, September 14th at 12:30 p.m. as poster event number 039:
“Alpha-Hydroxybutyrate and Linoleoyl-Glycerophosphocholine as New Markers of Fatty Liver Disease”, will be presented by Amalia Gastaldelli, Ph.D., CNRS, Research Director at the Cardiometabolic Risk Laboratory Institute of Clinical Physiology, National Research Council, Pisa, Italy; the study determined that raised plasma concentrations of Alpha-Hydroxybutyrate (α-HB) and Linoleoyl-Glycerophosphocholine (L-GPC), both produced in the liver, mark for the presence of fatty liver disease. Low L-GPC levels were also found to be specifically associated with hepatic insulin resistance.
Metabolon, Inc. has advanced the field of metabolomics by pioneering and patenting the industry’s leading biochemical biomarker discovery and profiling platform. It has developed the technology to quickly identify and measure all of the biochemicals in a biological sample through its proprietary global processing method. Through the generation and interpretation of data, this method provides a precise understanding of disease etiology and drug action, and advances personalized medicine beyond what genomics and other approaches can promise. Metabolon’s expertise is being embraced by a wide range of pharmaceutical, biotechnology, food and agricultural companies. Metabalytics, its biomarker discovery and analysis business, has completed over 320 client studies and processed over 30,000 samples for customers in 2010 alone. Building on its expertise in biochemistry understanding, Metabolon is also developing proprietary diagnostic tests to determine and track disease progression. For more information about Metabolon, please visit www.metabolon.com or contact Matt Zaske at email@example.com (919) 919-595-2200.
Lippert/Heilshorn & Assoc.